TCG CROSSOVER MANAGEMENT LLC
Q1 2022 Form 13-F
PALO ALTO, CALIFORNIA
CIK 0001839948
· CRD 311718
· SEC-registered investment adviser
$249.1M Reported Value Total
TCG CROSSOVER MANAGEMENT, LLC reports 1 total accounts under management (AUM). There are 1 discretionary accounts valued at $880,078,419, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
3 funds
· $3.8B gross asset value
Other: $3.8B
Source: Form ADV filed 2026-05-29
Reported value
$249.1M
Quarter over quarter
-11.0%
Holdings
20
Top-10 concentration
78.8%
Key People
Form ADV owners & control persons
Chen Ming Yu
MANAGING PARTNER
Craig David Skaling
CHIEF OPERATING OFFICER AND CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2022 13F record
Q1 2022 13F filing summary
| Period of report | March 31, 2022 |
|---|---|
| Filed | May 16, 2022 |
| Form | 13F-HR |
| Reported value | $249.1M |
| Positions | 20 |
| Change in reported value | +16.6% |
| New positions | 5 |
| Exited positions | 0 |
| Position turnover | 25.0% |
| Top-10 concentration | 78.8% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
57 | $3.5B |
|
Q2 2026 13F
Filed Aug 14, 2026
|
54 | $4.2B |
|
Q1 2026 13F
Filed May 15, 2026
|
49 | $3.5B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
43 | $3.0B |
|
Q3 2025 13F
Filed Nov 17, 2025
|
40 | $2.0B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
37 | $875.5M |
|
Q1 2025 13F
Filed May 14, 2025
|
37 | $733.1M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
38 | $1.0B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
36 | $1.2B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
32 | $959.5M |
|
Q1 2024 13F
Filed May 15, 2024
|
33 | $1.3B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
29 | $901.7M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
26 | $679.1M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
22 | $609.8M |
|
Q1 2023 13F
Filed May 15, 2023
|
22 | $513.0M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
21 | $566.6M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
21 | $333.4M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
22 | $235.4M |
|
Q1 2022 13F
Filed May 16, 2022
|
20 | $249.1M |
|
Q4 2021 13F
Filed Feb 18, 2022
|
15 | $213.6M |
Top 20 holdings · Q1 2022
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ISEE Iveric Bio, Inc. | $42.4M | 17.01% |
| 2 | VRDN Viridian Therapeutics Inc | $24.3M | 9.75% |
| 3 | COGT Cogent Biosciences, Inc. | $22.3M | 8.96% |
| 4 | ACRS Aclaris Therapeuitics, Inc. | $19.7M | 7.92% |
| 5 | GERN Geron Corporation | $19.4M | 7.8% |
| 6 | CBAY CymaBay Therapeutics, Inc. | $18.4M | 7.37% |
| 7 | AVTE Aerovate Therapeutics, Inc. | $16.3M | 6.55% |
| 8 | KDNY Chinook Therapeutics, Inc. | $14.4M | 5.79% |
| 9 | TYRA Tyra Biosciences, Inc. | $9.6M | 3.85% |
| 10 | TNGX Tango Therapeutics, Inc. | $9.5M | 3.82% |
| 11 | ALPN Alpine Immune Sciences, Inc. | $9.3M | 3.72% |
| 12 | KURA Kura Oncology, Inc. | $8.1M | 3.27% |
| 13 | MRUS Merus N.V. | $7.9M | 3.18% |
| 14 | AKUS Akouos, Inc. | $6.4M | 2.57% |
| 15 | DNTH Magenta Therapeutics, Inc. | $6.2M | 2.47% |
| 16 | TRDA Entrada Therapeutics, Inc. | $6.1M | 2.46% |
| 17 | ZLAB Zai Lab LTD-ADR | $4.2M | 1.68% |
| 18 | PRDS Pardes Biosciences, Inc. | $1.7M | 0.66% |
| 19 | ANAB AnaptysBio, Inc. | $1.4M | 0.58% |
| 20 | ELEV Elevation Oncology, Inc. | $1.4M | 0.56% |
Values as reported on the Q1 2022 Form 13F. Every position is in the holdings table below.